Embiosys Inc.

Funding and NIH signals

• NIH award NIH awarded $870K (SBIR Phase II 5R44CA310518-02, continuation, notice Sep 11, 2026). NIH RePORTER 5R44CA310518-02 (Sep 11, 2026)
  Evidence (1 event)

  • Sep 11, 2026 · NIH RePORTER 5R44CA310518-02
    Organization: EMBIOSYS INC.; City/State: North Andover, MA; Project number: 5R44CA310518-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 870482; Administering IC: National Cancer Institute; Project title: CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals